Grasse BIOTECH

grassebiotech.fr

Grasse BIOTECH - Hotel of innovation companies and support of startups in the field of cosmetologies, biotechnologies, health, life sciences and scientific research and analysis activities of the Pays de Grasse, benefits from added value linked to a privileged project accelerator environment. On the ArômaGrasse Business Park where are hosted more than 15 companies such as: Perfume Cosmetic World, TOMCOS, SelectArôme ... mostly PASS (Perfumes, Aromas, Scents, Flavors). In connection with Espace Jacques-Louis Lions where are located: o the InnovaGrasse business incubator, o the University of Nice Sophia-Antipolis: training in fine chemistry master 2 FOQUAL, its students, professors and researchers in a place conducive to teaching and research (classrooms, laboratories, exchange rooms ...), o Technological and regulatory resources represented by the PASS Competitiveness Cluster and its partnership analytical chemistry platform, whose objective is to strengthen R & D by bringing researchers from the academic sector and the private sector together in a single location (certification and authentication). ingredients). In an already existing network of support for creation and innovation, Grasse BIOTECH thus makes it possible to cover the entire chain of support to businesses: from creation to their long-term presence on the territory of the Communauté d'Agglomération du Pays de Grasse. Grasse BIOTECH is funded with the support of the European Union with the European Regional Development Fund, the Regional Council PACA and the Departmental Council of the Alpes-Maritimes.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Cell and Gene Therapy, Industrial Impact

ENLAZA THERAPEUTICS LAUNCHES WITH $61 MILLION FINANCING TO ADVANCE THE FIRST COVALENT BIOLOGIC THERAPEUTIC PLATFORM

Enlaza Therapeutics | December 19, 2022

news image

Enlaza Therapeutics, the first covalent biologic platform company, announced its official launch with the closing of $61 million in seed financing. The financing was led by Avalon Ventures and joined by Lightspeed Venture Partners, Frazier Life Sciences, and Samsara BioCapital. The financing will be used to further advance Enlaza’s proprietary War-LockTM platform and build a pipeline of covalent biologics with an initial focus on developing novel, differentiated cancer therapeutics with ta...

Read More

Industrial Impact

SIGA ANNOUNCES ONCOLOGY COLLABORATION WITH KALIVIR IMMUNOTHERAPEUTICS

SIGA Technologies Inc. | July 16, 2022

news image

SIGA Technologies, Inc. a commercial-stage pharmaceutical company focused on the health security market, today announced a collaboration with KaliVir Immunotherapeutics to make TPOXX® available for use with KaliVir’s proprietary oncolytic vaccinia immunotherapy platform. This novel oncolytic platform includes multiple proprietary genetic modifications that can be combined to generate a unique oncolytic virus that has been optimized for systemic delivery and anti-tumor immune stimulatio...

Read More

Medical

CARDEA BIO COMPLETES PLANNED LAUNCH OF CRISPR QC

Cardea Bio | April 06, 2022

news image

Today, Cardea Bio, Inc. - the world's only mass producer of biocompatible semiconductors - announced a significant milestone with the launch of CRISPR QC Inc. as a separate business using Cardea's CRISPR-chip™ technology for a range of quality control services for CRISPR gene editing. This milestone is an important move for Cardea Bio on its mission to realizing real-world applications of their BPU™ (Biosignal Processing Unit) Platform. After recently establish...

Read More

BOOST BIOMES ANNOUNCES CLOSE OF SERIES A AND CO-DEVELOPMENT AGREEMENT WITH LEAD INVESTOR, YARA INTERNATIONAL, FOR BIOSTIMULANTS PRODUCTS

Boost Biomes | June 25, 2020

news image

US-based food and agriculture biotech startup Boost Biomes and global crop nutrition company, Yara International ASA, announced today the close of Boost's USD 5 million series A equity round as well as a joint development agreement between the two companies. Yara's investment amounts to USD 3 million. Existing investors, including Viking Global Investors and Y Combinator, participated in the close.With this partnership in place, Boost and Yara will expand current efforts to co-deve...

Read More
news image

Cell and Gene Therapy, Industrial Impact

ENLAZA THERAPEUTICS LAUNCHES WITH $61 MILLION FINANCING TO ADVANCE THE FIRST COVALENT BIOLOGIC THERAPEUTIC PLATFORM

Enlaza Therapeutics | December 19, 2022

Enlaza Therapeutics, the first covalent biologic platform company, announced its official launch with the closing of $61 million in seed financing. The financing was led by Avalon Ventures and joined by Lightspeed Venture Partners, Frazier Life Sciences, and Samsara BioCapital. The financing will be used to further advance Enlaza’s proprietary War-LockTM platform and build a pipeline of covalent biologics with an initial focus on developing novel, differentiated cancer therapeutics with ta...

Read More
news image

Industrial Impact

SIGA ANNOUNCES ONCOLOGY COLLABORATION WITH KALIVIR IMMUNOTHERAPEUTICS

SIGA Technologies Inc. | July 16, 2022

SIGA Technologies, Inc. a commercial-stage pharmaceutical company focused on the health security market, today announced a collaboration with KaliVir Immunotherapeutics to make TPOXX® available for use with KaliVir’s proprietary oncolytic vaccinia immunotherapy platform. This novel oncolytic platform includes multiple proprietary genetic modifications that can be combined to generate a unique oncolytic virus that has been optimized for systemic delivery and anti-tumor immune stimulatio...

Read More
news image

Medical

CARDEA BIO COMPLETES PLANNED LAUNCH OF CRISPR QC

Cardea Bio | April 06, 2022

Today, Cardea Bio, Inc. - the world's only mass producer of biocompatible semiconductors - announced a significant milestone with the launch of CRISPR QC Inc. as a separate business using Cardea's CRISPR-chip™ technology for a range of quality control services for CRISPR gene editing. This milestone is an important move for Cardea Bio on its mission to realizing real-world applications of their BPU™ (Biosignal Processing Unit) Platform. After recently establish...

Read More
news image

BOOST BIOMES ANNOUNCES CLOSE OF SERIES A AND CO-DEVELOPMENT AGREEMENT WITH LEAD INVESTOR, YARA INTERNATIONAL, FOR BIOSTIMULANTS PRODUCTS

Boost Biomes | June 25, 2020

US-based food and agriculture biotech startup Boost Biomes and global crop nutrition company, Yara International ASA, announced today the close of Boost's USD 5 million series A equity round as well as a joint development agreement between the two companies. Yara's investment amounts to USD 3 million. Existing investors, including Viking Global Investors and Y Combinator, participated in the close.With this partnership in place, Boost and Yara will expand current efforts to co-deve...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us